Trial Results Demonstrate Diagnostic Performance of Aurora Dedicated Breast MRI System Over Whole-Body Breast MRI

October 2, 2012 — A clinical trial published in the October issue of Radiology demonstrates that Aurora Imaging Technology’s 1.5T dedicated breast MRI (magnetic resonance imaging) system led to better diagnostic performance for all metrics (sensitivity, specificity, negative predictive value [NPV], positive predictive value [PPV] and receiver operating characteristic [ROC] area) than has been historically reported in trials for breast MRI on whole-body MRI scanners. In addition, the low frequency of false positive and false negative findings associated with the dedicated breast MRI system allows for use of breast MRI with low risk of patient harm in both the screening and diagnostic environments. The study was managed by ACR Image Metrix, the American College of Radiology’s clinical research organization.

“The results of this multicenter trial validate what we have suspected for many years, which is, using a dedicated MRI system optimized for breast imaging results in superior diagnostic performance. In addition, we were able to demonstrate consistency of performance across a variety of breast imaging centers, university, community hospital and independent breast centers,” said Steven Harms, M.D., primary investigator for the study.

The study included more than 900 patients and resulted in sensitivity and specificity for the dedicated breast MRI system of 92 percent (92/100) and 88.9 percent (741/834), respectively. For all cases, the NPV was 98.9 percent (741/749), and the NPV for screening cases was 100 percent (326/326). The area under the ROC curve was 94.2 percent. The false positive rate was 93/834 (11 percent) for all cases, but only 16/326 (4.7 percent) for the screening cohort.

Alan Hollingsworth, M.D., medical director, breast surgeon at Mercy Women’s Center at Mercy Health Center, and study investigator added, “False positive rates from previously reported trials using whole-body breast MRI have typically been between 30-50 percent. These studies have led to criticism of breast MRI for its high false positive rates, resulting in unnecessary biopsies, surgical procedures and anxiety for the patient. The dedicated breast MRI system offers a significant improvement in performance. Even within the 93 false positives, 25 (27 percent) were high-risk histologies for which excision is often recommended. This kind of performance should provide breast radiologists and surgeons alike a higher level of diagnostic confidence, and could have significant impact on the role of breast MRI”.

For more information: www.auroramri.com


Related Content

News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Radiology Business

April 17, 2024 — VISTA.AI announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI ...

Time April 17, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | ACR

April 15, 2023 — The American College of Radiology (ACR) released an update to its ACR Appropriateness Criteria (ACR AC) ...

Time April 13, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
Subscribe Now